1. CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.

    Prostate Cancer 2014:294575 (2014) PMID 25431674 PMCID PMC4241328

    Although the causes of prostate cancer are largely unknown, previous studies support the role of genetic factors in the development of prostate cancer. CHEK2 plays a critical role in DNA replication by responding to double-stranded breaks. In this review, we provide an overview of the current kn...
  2. Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs.

    American Journal of Tropical Medicine and Hygiene 77(6 Suppl):198 (2007) PMID 18165493

    Despite considerable efforts by multiple governmental and nongovernmental organizations to increase access to artemisinin-based combination therapies (ACTs), these life-saving antimalarial drugs remain largely unaffordable to the most vulnerable populations. The cost of artemisinin derivatives, ...
  3. Straight talk from... Victoria Hale.

    Nature Medicine 13(11):1274 (2007) PMID 17987011

  4. Enteric vaccines for pediatric use. Workshop summary.

    Vaccine 23(46-47):5432 (2005) PMID 16286159

    Diarrheal diseases remain a major cause of death in children under 5 in less developed countries (LDCs). Vaccine development and implementation offers the best near-term approach to alleviating this problem. For this reason, a workshop to examine the possibilities for making enteric vaccines ava...
  5. Enteric vaccines for pediatric use:Workshop summary

    Vaccine 23(46):5432 (2005)

    Diarrheal diseases remain a major cause of death in children under 5 in less developed countries (LDCs). Vaccine development and implementation offers the best near-term approach to alleviating this problem. For this reason, a workshop to examine the possibilities for making enteric vaccine...
  6. Creating more paths to hope.

    Newsweek 144(23):80 (2004) PMID 15605728

  7. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients.

    Journal of Clinical Pharmacology 43(6):624 (2003) PMID 12817525

    The pharmacokinetics and pharmacodynamics of ziconotide were assessed over a 48-hour period following intrathecal (i.t.) administration (1, 5, 7.5, or 10 micrograms) to 22 patients with chronic, nonmalignant pain. Plasma and cerebrospinal fluid (CSF) samples were obtained over a 24-hour period. ...
  8. New hope for neglected diseases.

    Expert Opinion on Emerging Drugs 7(2):209 (2002) PMID 15989544

  9. ADAPTING PHARMACOKINETIC PROPERTIES OF A HUMANIZED ANTI-INTERLEUKIN-8 ANTIBODY FOR THERAPEUTIC APPLICATIONS USING SITE-SPECIFIC PEGYLATION

    Cytokine 16(3):106 (2001)

    A neutralizing anti-interleukin-(IL-)8 monoclonal antibody was humanized by grafting the complementary determining regions onto the human IgG framework. Subsequent alanine scanning mutagenesis and phage display enabled the production of an affinity matured antibody with a >100-fold improvem...
  10. Analysis of Neurotrophin/Receptor Interactions with a gD-Flag-Modified Quantitative Kinase Receptor Activation (gD.KIRA) Enzyme-Linked Immunosorbent Assay

    Experimental Cell Research 234(2):354 (1997)

    A rapid, sensitive, and high-capacity assay has been developed to quantify ligand-induced receptor tyrosine kinase activation in terms of receptor phosphorylation. The assay, termed a “kinase receptor activation” or KIRA-ELISA, utilizes two separate microtiter plates, one for cell cult...